Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Multiparametric chemical exchange saturation transfer MRI detects metabolic changes in breast cancer following immunotherapy

Fig. 2

Metabolic profiles of in vitro cell extracts. a Exemplary CEST-MRI-derived MTRasym spectra of 4T1 (yellow), 67NR (purple) or T-cell (green) extracts. b-d Quantitative MTRasym for Glc-, 2 ppm- and APT-weighted CEST contrast of the different cell extracts. Extracts of highly malignant 4T1 breast cancer cells demonstrated higher Glc- and APT-weighted and lower 2 ppm-weighted CEST contrast compared to low malignant 67NR cell extracts. T-cell extracts showed higher CEST contrast at all three examined frequency offsets. e–g Metabolite concentrations (glucose (Glc), creatine (Cr), amide protons (APT)) quantified by 1H-NMR spectroscopy, with similar metabolic differences between the cell lines than observed with CEST-MRI. Each dot represents one sample, with horizontal lines indicating minimum, mean and maximum values of each respective group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page